PHIO - MCAP CO - Phio Pharmaceuticals

The historical price action of Phio Pharmaceuticals (PHIO) demonstrates the trajectory of an RNA therapy innovator that developed the unique INTASYL system to combat skin cancer. Current market capitalization stands at 0.01. The business maintains resilience due to a lack of debt, although the pace of research spending requires attention. Stability of supplies to medical centers is guaranteed through the use of specialized refrigerated transport for the shipment of fragile biologics.

Market capitalization reflects the total value of all the issuer's shares, serving as an objective measure of the business's market size. This metric aggregates the current quote and the volume of the issue, which is clearly demonstrated by the company's market capitalization history. For the investor, this indicator serves as a tool for assessing the asset's liquidity and fundamental value. However, the volatility of Phio Pharmaceuticals (PHIO) is intensifying due to geopolitical barriers in the export of genetic equipment. Sanctions restrictions in the field of RNA therapy directly impact the company's investment attractiveness.